No Data
Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7
Baird Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7
Optimism for Taysha Gene Therapies: Promising Preclinical Data and Upcoming Catalysts Drive Buy Rating
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $6
Taysha Gene Therapies to Present Biodistribution Data From an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why
I Am 102927471 :